|
|
|
Volumn 23, Issue 1 SUPPL. 2, 1996, Pages 55-59
|
|
Chemotherapy for advanced breast cancer: A current perspective
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOTOXIC AGENT;
DOCETAXEL;
DOXORUBICIN;
EPIRUBICIN;
FLUOROURACIL;
GOSSYPOL;
GRANULOCYTE COLONY STIMULATING FACTOR;
GROWTH FACTOR RECEPTOR;
GYRASE INHIBITOR;
IRINOTECAN;
MITOMYCIN;
MITOXANTRONE;
NAVELBINE;
PACLITAXEL;
TAXANE DERIVATIVE;
TOPOTECAN;
VINCA ALKALOID;
ADVANCED CANCER;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DRUG MEGADOSE;
EDEMA;
HUMAN;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
BRIDGED COMPOUNDS;
CHEMOTHERAPY, ADJUVANT;
CONTINUITY OF PATIENT CARE;
COSTS AND COST ANALYSIS;
DECISION MAKING;
DRUG DESIGN;
FEMALE;
GROWTH INHIBITORS;
HUMANS;
LYMPHATIC METASTASIS;
NEOPLASM STAGING;
PALLIATIVE CARE;
QUALITY OF LIFE;
RISK ASSESSMENT;
TAXOIDS;
|
|
EID: 0029981617
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (25)
|
|
References (0)
|
